Page last updated: 2024-10-23

biperiden and DDPAC

biperiden has been researched along with DDPAC in 1 studies

Biperiden: A muscarinic antagonist that has effects in both the central and peripheral nervous systems. It has been used in the treatment of arteriosclerotic, idiopathic, and postencephalitic parkinsonism. It has also been used to alleviate extrapyramidal symptoms induced by phenothiazine derivatives and reserpine.
biperiden : A member of the class of piperidines that is N-propylpiperidine in which the methyl hydrogens have been replaced by hydroxy, phenyl, and 5-norbornen-2-yl groups. A muscarinic antagonist affecting both the central and peripheral nervous systems, it is used in the treatment of all forms of Parkinson's disease.

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's1 (100.00)2.80

Authors

AuthorsStudies
Gallucci, M1
Pallucca, C1
Di Battista, ME1
Bergamelli, C1
Fiore, V1
Boccaletto, F1
Fiorini, M1
Perra, D1
Zanusso, G1
Fenoglio, C1
Serpente, M1
Galimberti, D1
Bonanni, L1

Other Studies

1 other study available for biperiden and DDPAC

ArticleYear
Anti-Cholinergic Derangement of Cortical Metabolism on 18F-FDG PET in a Patient with Frontotemporal Lobar Degeneration Dementia: A Case of the TREDEM Registry.
    Journal of Alzheimer's disease : JAD, 2020, Volume: 74, Issue:4

    Topics: Aged; Biperiden; Cerebral Cortex; Fluorodeoxyglucose F18; Frontotemporal Dementia; Humans; Male; Men

2020